Effects of nasal high-flow therapy on heart function in pulmonary hypertension patients
Official title: Physiological Evaluation of the Hemodynamic Effects of Nasal High Flow in Patients Being Explored by Right Heart Catheterisation and Echocardiography for Suspected or Followed Precapillary Pulmonary Hypertension
Run by ADIR Association · NCT06079151 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests if using nasal high-flow therapy can improve heart function in patients with suspected pulmonary hypertension.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | ADIR Association Academic / other |
| Locations | 1 site (Rouen) |
| Trial ID | NCT06079151 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients undergoing right heart catheterization for suspected or monitored precapillary pulmonary hypertension.
✕Probably not a fit
Patients requiring more than 21% oxygen during the procedure or those with severe cardiac conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the hemodynamic effects of nasal high-flow therapy in patients suspected of having precapillary pulmonary hypertension. It aims to measure changes in cardiac output during right heart catheterization and echocardiography, hypothesizing that nasal high-flow will enhance cardiac output. The study will utilize echocardiography to assess the sensitivity of detecting cardiovascular changes resulting from this therapy.
Why it matters
Potential benefit: If successful, this approach could improve the management of pulmonary hypertension by enhancing cardiac function.
How similar studies have gone: While similar studies have explored high-flow therapies, this specific approach in the context of pulmonary hypertension is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: - patient addressed for right heart catheterization for pulmonary hypertension suspicion or follow-up. Exclusion Criteria: * necessity of FiO2 \>21% during right heart catheterization * intracardiac shunt * grade 4 tricuspid insufficiency * complete arrhythmia due to atrial fibrillation * Pregnant or breastfeeding women or women of childbearing age without an effective method of contraception * protected adult patient (tutorship or curatorship) * patient deprived of liberty by court or administrative decision * refusal of patient participation or consent * patient for whom the measurement of pulmonary arterial pressures during right heart catheterization is impossible * patient for whom, during the etiological assessment of pulmonary hypertension, the diagnosis of precapillary pulmonary hypertension cannot be confirmed and classified in groups 1, 3 or 4.
Where it's running
-
ROUEN university hospital
Rouen, France Recruiting
Study contacts
- Principal investigator: Elise ARTAUD-MACARI, MD — ADIR Association
- Study coordinator: Elise ARTAUD-MACARI, MD
- Email: elise.artaud-macari@chu-rouen.fr
- Phone: +33 2 32 88 59 92
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Levosimendan to see if it helps the heart after PEA in CTEPH
This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.
-
Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD
This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.
-
Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension
This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER
This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.
-
Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.